drugset
drugset / Trial / NCT04314505

Opioid-Sparing Protocol Comparing With Opioid-based Protocol After Bilateral Total Knee Arthroplasty

NCT04314505 ↗

Phase 4 Unknown 56 enrolled Taipei Veterans General Hospital, Taiwan
RandomizedParallel-groupTriple-blindTreatment

Summary

The concern for the opioid use in the total knee arthroplasty continues to rise in recent decades. Historically, the total knee arthroplasty consumed high doses opioids in the postoperative periods. Compared to the Opioid-Based patient controlled analgesia(PCA), the opioid-sparing protocol may have benefits to decrease the concerns of the opioid use and opioid-related complication and provides the equivalent efficacy for pain control. The purpose of this trial in to provide a novel opioid-sparing protocol (OSP) to evaluate the efficacy for pain control and reducing the immediate postoperative opioid consumption.

Timeline

Start
2020-03-20
Primary completion
2020-06-20
Completion
2020-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Parecoxib Small molecule 40 mg Intravenous
Background Acetaminophen Small molecule 500 mg Oral
Background Bupivacaine Other / unclassified 10 ml Other
Background Celecoxib Other / unclassified 200 mg Oral
Comparator Morphine Other / unclassified 0.01 mg/kg Intravenous
Comparator Morphine Other / unclassified 2 mg Intravenous
Comparator Morphine Other / unclassified 4 mg Intravenous
Comparator Morphine Other / unclassified 40 mg Intravenous

Indications

No indication recorded.